The Latest
-
Getty Images
AstraZeneca’s at-home flu vaccine is a breakthrough that could pave the way for others
FluMist Home could be a test case for at-home vaccines against a backdrop of challenging regulatory shifts.
-
Getty Images
Top pharma industry conferences in 2026
Where pharma leaders will converge, discuss and navigate the industry’s shifting landscape in 2026.
-
Getty Images
Will the first fibromyalgia drug in 15 years deliver a breakthrough in pain?
The new treatment may only offer modest benefits, but could gain traction in a market with few other options.
-
Getty Images
As obesity M&A heats up, pharmas could get ‘blinded by opportunity’
With companies racing to secure GLP-1-related assets, there may be risks for moving too fast.
-
Getty Images
Is pharma’s IRA pricing battle running out of steam?
Despite recent court losses, the legal tides could still turn in the industry’s favor.
-
Sean Anthony Eddy via Getty Images
Why Xoma, a drug royalty firm, is hunting biotech ‘zombies’
The collapse in value of many biotechs over the past few years has created an opportunity for specialists like Xoma to “do the right thing” for the ecosystem and liquidate them, its executives say.
-
Dominik Bindl via Getty Images
Can a multibillion-dollar deal put Pfizer in the obesity big leagues?
After a couple failed attempts on its own, Pfizer is hitting the M&A gas to bring in candidates that could help it become a weight loss heavyweight.
-
Getty Images
Pharma’s next generation of blockbuster antibodies takes a ‘more is better’ approach
Why multi-specific antibodies are seeing a fresh surge of industry buzz.
-
Getty Images
Q&ALilly’s Alzheimer’s efforts depend on newer, better biomarkers and diagnostics
The pharma giant’s R&D in Alzheimer’s didn’t end with last year’s Kisunla approval, and diagnostics could define where the company goes next.
-
Getty Images
With DTC ads under fire, pharma companies need to pivot
An executive order from HHS doesn’t prohibit direct outreach to consumers, but drugmakers will need to rethink their outreach strategies.
-
Getty Images
3 FDA approval firsts that could be around the corner
Several market-altering decisions are on the agency’s docket for the rest of 2025.
-
Getty Images
How pharma can play a role in the $1 trillion healthcare reinvention
A report from PwC takes a long-term approach to the shifts in healthcare and finds that efficiency in R&D and adaptable business models will define the drugmaker of the future.
-
Getty Images
AI agents are coming to pharma. Here’s what it means for clinical trials.
The high-tech helpers could autonomously navigate tedious tasks — but have to be carefully implemented.
-
Getty Images
Biotech’s VC slowdown forces young drugmakers to adapt in the ‘valley of death’
Amid the sector’s long winter, startups are shifting gears to extend their cash runways.
-
Permission granted by Takeda
From atop Mt. Fuji, a Takeda team heralds a need for human plasma
The climb aimed to raise money and awareness as Takeda ramps up its plasma-derived therapy presence in Japan.
-
Sean Gallup via Getty Images
Moderna and BioNTech pioneered mRNA vaccines. But who will make a mark in therapeutics?
While mRNA changed the game in vaccines, leveraging the technology to develop treatments has been trickier to navigate.
-
Getty Images
4 years from clinic to approval — Precigen’s ‘unprecedented’ FDA nod and what comes next
The company scored the first-ever approval to treat a potentially deadly infection leveraging its gene therapy platform.
-
Getty Images
Ozempic for cancer? Signs point to potential benefits of GLP-1s in oncology.
Growing research suggests various ways weight loss drugs could have an impact in cancer care.
-
Dragos Condrea via Getty Images
A new class of sleep drugs draws Wall Street’s attention
Clinical trial data presented this weekend show drugs from Takeda, Alkermes and Eisai significantly helped people with narcolepsy, heralding a new era of sleep medicine.
-
Getty Images
Pharma’s new boomtown? Why drugmakers are setting up shop in a small Swiss city.
While the EU and UK attempt to lure scientists with new financial incentives, Basel’s stable economy and emphasis on science remains a draw.
-
Getty Images
Inside pharma’s race to deliver new treatments for dwarfism
By targeting the underlying genetic mutation that drives the condition, researchers hope to increase height and address debilitating complications.
-
Getty Images
Q&ACan new Alzheimer’s tests help clear the way for the next generation of therapies?
A tau-related blood test could offer more insight in early-disease pathology to the complicated Alzheimer’s disease space.
-
Andrew Harnik via Getty Images
At Senate hearing, lawmakers express dissatisfaction with RFK Jr.’s vaccine moves
Robert F. Kennedy Jr. faced criticism Thursday even from Republican lawmakers over changes to federal vaccine policy as well as a leadership crisis at the CDC.
-
Getty Images
International appeal: Europe and UK lure US scientists with financial incentives
With slashed budgets and decimated research programs, American scientists are increasingly looking for career opportunities abroad.
-
Getty Images
Why drugmakers may need to borrow from quantum theory to confront tariff and pricing threats
With so many unknowns surrounding regulatory and policy shifts, pharma companies might need to consider fundamental changes to how they operate, a Deloitte analyst said.
